The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

During a live event, Deborah Wong, MD, PhD, discussed the role of EBV and challenges in nasopharyngeal cancer diagnosis with ...

A panelist discusses how chronic graft-versus-host disease affects 30-70% of allogeneic transplant patients across eight ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical ...

Nini Wu, MD, MBA, discusses long-term investments aimed at stabilizing and strengthening the future of community oncology ...

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the ...